APVO AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
The stock has received the highest rating for its value, but its dividend score is below 2. If the company starts distributing dividends, it may yield even better investment results.
APVO Current Performance
0.78%
Aptevo therapeutics inc
1.19%
Avg of Sector
1.11%
S&P500
Top 10 High Relevance to APVO
| Symbol | Company Name | Value | Trend | Swing Trading | Whale Interest | Dividend | Add to Watchlist |
|---|---|---|---|---|---|---|---|
ANRO | Alto neuroscience inc | - | 3 | 2 | 3 | 1 | |
AVBP | Arrivent biopharma inc | - | 4 | 3 | 3 | 1 | |
BFRI | Biofrontera inc | - | 3 | 2 | 1 | 1 | |
EYEN | Eyenovia inc | 2 | 4 | 2 | 1 | 1 | |
PSNL | Personalis inc | 3 | 3 | 2 | 2 | 1 |
- ANRO Alto neuroscience incValue -Trend 3Swing Trading 2Whale Interest 3Dividend 1See more
APVO Profile
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing novel immunotherapy candidates for the treatment of different forms of cancer. It has developed two versatile and enabling platform technologies for rational design of precision immune modulatory drugs. Its lead clinical candidates, APVO436 and ALG.APV-527, and preclinical candidates, APVO603 and APVO711, are developed using its ADAPTIR modular protein technology platform. Its preclinical candidate APVO442 is developed using its ADAPTIR-FLEX modular protein technology platform. APVO436 is a bispecific ADAPTIR that is designed to engage CD3 and CD123 to redirect T-cells to destroy leukemia cells expressing the target CD123 molecule on their surface. ALG.APV-527 is a novel investigational bispecific ADAPTIR candidate. APVO603 is a preclinical dual agonist bispecific ADAPTIR candidate designed to simultaneously target 4-1BB (CD137) and OX40 (CD134), both members of the TNF-receptor family.